Novocure Ltd — News

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-07-27 13:01:15

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-07-27 11:03:48

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

zacks.com - 2026-07-27 10:29:05

NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised to $0–$15M, yet true cash generation remains elusive. Optune Pax's early uptake is promising but too preliminary to signal sustainable growth; its Q2 contribution was just $1.6M.

seekingalpha.com - 2026-07-24 13:45:46

Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability. NVCR's operating leverage is improving, with gross margins at 78% and net loss narrowing significantly, driven by 18% global active patient growth and expanding indications. Optune Pax's early launch shows promising adoption across academic and community settings, with repeat prescribing indicating potential for durable utilization and revenue upside.

seekingalpha.com - 2026-07-24 10:21:56

NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-23 13:00:50

NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.

zacks.com - 2026-07-23 09:16:05

NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.

marketbeat.com - 2026-07-23 09:08:04

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to exte

gurufocus.com - 2026-07-23 08:00:00

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure. “We continue to lau.

businesswire.com - 2026-07-23 07:00:00

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-16 11:06:22

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-07-16 10:00:00

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-14 18:24:00

NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio, with full-year 2026 revenue guidance raised to $690–$710 million.

seekingalpha.com - 2026-07-10 15:01:54

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-07-09 17:40:00

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-07 17:57:00

NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.

zacks.com - 2026-07-01 14:01:08

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company's financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access.

businesswire.com - 2026-07-01 07:00:00

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-06-30 17:16:00

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. “Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival.

businesswire.com - 2026-06-30 07:00:00

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-06-25 19:36:00

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.

fool.com - 2026-06-24 14:45:21

Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.

fool.com - 2026-06-22 10:39:30

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure L

gurufocus.com - 2026-06-20 14:00:00

LOS ANGELES--(BUSINESS WIRE)---- $NVCR--NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm.

businesswire.com - 2026-06-20 13:34:00

Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.

fool.com - 2026-06-19 12:50:34

Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026.

prnewswire.com - 2026-06-18 21:41:00

Novocure ​said on ‌Thursday ​that ​its cancer ⁠treatment ​for ​newly diagnosed brain ​tumors ​did not ‌meet ⁠the main ​goal ​of ⁠a ​late-stage ​study.

reuters.com - 2026-06-18 07:08:25

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the subsequent maintenance phase of treatment (Maintenance Start Arm). The trial did not demonstrate a statistically significant improvement in the primary endpoint.

businesswire.com - 2026-06-18 07:00:00

This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.

fool.com - 2026-06-09 10:12:12

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

fool.com - 2026-05-05 08:45:00

Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

zacks.com - 2026-05-04 10:16:16

NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed.

seekingalpha.com - 2026-05-01 12:35:10

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-30 14:41:46

NovoCure (NVCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.31 per share a year ago.

zacks.com - 2026-04-30 09:35:21

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was a very strong start to the year for Novocure and we are pleased with the progress made across our commercial and clinical programs,” said Frank.

businesswire.com - 2026-04-30 07:00:00